Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview.

Autor:	Zhang J; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.; Department of Nuclear Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China., Kang F; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China., Wang X; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China., Chen X; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China., Yang X; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.; Department of Central Laboratory, Peking University First Hospital, Beijing, China.; Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Beijing, China.; International Cancer Institute, Peking University Health Science Center, Beijing, China; and., Yang Z; Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Beijing, China; 13909245902@163.com yangxing2017@bjmu.edu.cn.; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China., Wang J; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China; 13909245902@163.com yangxing2017@bjmu.edu.cn.
Jazyk:	angličtina
Zdroj:	Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 May 06; Vol. 65 (Suppl 1), pp. 38S-45S. Date of Electronic Publication: 2024 May 06.
DOI:	10.2967/jnumed.123.266314
Abstrakt:	Radiopharmaceuticals play a critical role in nuclear medicine, providing novel tools for specifically delivering radioisotopes for the diagnosis and treatment of cancers. As the starting point for developing radiopharmaceuticals, cancer-specific biomarkers are important and receive worldwide attention. This field in China is currently experiencing a rapid expansion, with multiple radiotracers targeting novel targets being developed and translated into clinical studies. This review provides a brief overview of the exploration of novel imaging targets, preclinical evaluation of their targeting ligands, and translational research in China from 2020 to 2023, for detecting cancer, guiding targeted therapy, and visualizing the immune microenvironment. We believe that China will play an even more important role in the development of nuclear medicine in the world in the future. (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu